List view / Grid view
GSK will pay up to $3.3 billion to acquire Affinivax, gaining access to its Multiple Antigen Presenting System (MAPS) technology and pneumococcal vaccine candidates.
Pfizer reveals co-administering its Prevnar 20™ pneumococcal vaccine and a booster dose of Comirnaty® COVID-19 vaccine was safe and immunogenic.
Merck announces positive results from a Phase III study evaluating Vaxneuvance™ against a pneumococcal conjugate vaccine in infants.
Researchers have discovered that a virus-like particle vaccine can prime the body's immune response and prevent the severe respiratory diseases...
European Medicines Agency accepts application seeking new indication for Prevenar 13®1 for prevention of pneumococcal pneumonia in adults
8 August 2014 | By Pfizer
Application includes data from Pfizer’s community-acquired pneumonia immunization trial in adults (CAPiTA)...
19 December 2011 | By GlaxoSmithKline
Move aims to protect millions more children in the world's poorest countries from pneumococcal disease...